Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monoxerutin (7-monohydroxyethylrutoside) is a semi-synthetic flavonoid and a member of the hydroxyethylrutoside family. It is primarily utilized as a venotonic and vasoprotective agent to alleviate symptoms associated with chronic venous insufficiency, such as edema, pain, and heavy legs. The drug acts by reducing capillary permeability and increasing capillary resistance, likely through the stabilization of the endothelial cell membrane and the inhibition of neutrophil activation and adherence. Additionally, monoxerutin possesses significant antioxidant properties, scavenging reactive oxygen species and inhibiting lipid peroxidation, which contributes to its protective effects on the microvasculature. It is commonly found as a major constituent in standardized mixtures of hydroxyethylrutosides used in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monoxerutin.